Investor's Business Daily on MSN21m
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...
Applied Materials Stock Slides as Earnings Miss Expectations, China Sales Decline
Applied Materials reported fiscal fourth-quarter earnings that missed analysts’ expectations, sending shares lower after the ...
Livewire Markets on MSN30m
Antimony will be anything but anti-money if critical minerals trade war breaks out
The prospect of another US-China trade war on Donald Trump’s return to the White House is largely viewed through the prism of ...